Beyond Rare Earths: How China Is Tightening Its Grip on Solar, Drones and Medicines

Rare Earths Were Just the Opening Move

For the better part of a decade, “rare earths” has been the word most often used to describe China’s leverage over global supply chains. Western politicians have delivered solemn speeches about critical minerals, launched multi-billion-dollar mining projects, and signed diplomatic pacts to break what they call a dangerous dependence on Chinese materials. Yet that focus, while important, has always been too narrow. China is not simply a supplier of rocks and refined metals. It has quietly built a much deeper system of control across the industrial technologies that the modern world needs to function — especially solar power, drone manufacturing and pharmaceutical production. In recent years, and particularly since the height of the pandemic, Beijing has made a strategic effort to ensure that other countries find it harder to shed their reliance on Chinese-made equipment, chemicals, technical know-how and manufacturing systems. The result is a new reality that many Western policymakers are only beginning to acknowledge: the challenge is not just import dependency, but a more complicated entanglement with Chinese technology at every stage of the supply chain. Export controls once understood as a rare response to rare earths have now become a broader tool of Chinese industrial statecraft. Governments in Washington, Brussels, London and Delhi are scrambling to understand what that means, because breaking away has become radically harder than anyone anticipated.

China’s official export control lists now include far more than the exotic minerals that made headlines. They extend to technologies used in the manufacture of solar cells, to components and software used in both civilian and military drones, and to a range of chemical processes and pharmaceutical manufacturing methods that most consumers have never heard of. Industry analysts and trade lawyers describe the shift as deliberate and systematic. Beijing appears to have realized that the West is willing to tolerate pain in the mining sector, but is far more vulnerable when the chokehold touches clean energy, defense supply chains and public health. That realization, say diplomats and economists, has transformed China’s approach to global trade policy. It is no longer enough to control raw materials. China wants to control the means of production, the knowledge needed to operate that production, and the next generation of technology as it is developed. In that sense, rare earths were simply the overture. The full opera is only now being performed, and its stage is the global infrastructure of modern manufacturing.

Solar Power: The Clean Energy Dependency Washington Ignored

The global solar industry is often presented as one of the great success stories of the energy transition. Solar panels have fallen in price by more than 90 percent over the last two decades, renewable energy capacity is expanding at record speeds, and countries around the world are racing to install photovoltaic systems on rooftops, farms and desert fields. But beneath that bright narrative sits an uncomfortable fact: virtually the entire solar manufacturing chain is concentrated in China. From polysilicon and ingots to wafers, cells and finished panels, Chinese factories and equipment makers dominate the market with a share that industry groups estimate at eighty to ninety-five percent in some key segments. This is not simply a question of cheaper labor or environmental standards, though those play a role. It is the product of decades of sustained industrial policy, massive subsidies, targeted financing, and the deliberate creation of a self-contained ecosystem. Chinese companies control the machines that cut silicon wafers, the chemicals used to purify raw material, the production lines that assemble modules, and the engineers who know how to run them. That ecosystem is precisely what Beijing has begun to protect.

The recent inclusion of certain solar manufacturing technologies on China’s export control list sent a quiet but powerful signal through the industry. Solar firms and foreign investors suddenly understood that even if they built factories outside China, using non-Chinese ownership and approved supply chains, they would still need to purchase crucial equipment and process technology from Chinese suppliers. Those purchases now require licenses that can be approved or rejected at Beijing’s discretion. It is a form of control that does not require an embargo. It merely creates uncertainty, and uncertainty is enough to stall investment. Western trade officials have spent months encouraging domestic solar production through subsidies and tax credits, but manufacturers have responded with a single recurring warning: it is not enough to build a factory. You need the tools that make the tools, and right now China is the gatekeeper of those tools. Some companies have begun to explore alternative routes, including production in India and Southeast Asia, but nearly every corner of the global solar industry still reaches back into the Chinese supply chain. The dream of a truly “China-free” solar supply chain remains, for the moment, more aspiration than plan.

Drones: When the Skies Are Still Controlled from Shenzhen

Few industries illustrate China’s dominance in advanced hardware as vividly as the drone sector. Whether the subject is consumer quadcopters, agricultural sprayers, filmmaking drones or small surveillance platforms, China has become the default producer of the global market. Shenzhen, in particular, has anchored an entire ecosystem of drone manufacturers, component suppliers, software developers and test facilities. Companies such as DJI have achieved a level of global market penetration that competitors in the United States and Europe have never approached. Western governments have tried to reduce that influence, particularly in sensitive public-sector applications. They have banned certain Chinese drone models from official use, encouraged local production, and established certification programs designed to create alternatives. Yet the reality on the ground, or rather in the air, is more complicated. Many Western drone start-ups still depend on Chinese parts. The flight controllers, brushless motors, lithium batteries, camera sensors, communication modules and even the plastic frames of many non-Chinese drones are produced in China or by Chinese-owned factories elsewhere. Some of the most advanced drone software stacks used in autonomous navigation and mapping were initially developed in China and remain most refined there.

China has also tightened its own export restrictions on drones and drone-related technology. The stated rationale, as officially announced, is preventing the use of civilian drones for military purposes and guarding national security. That logic is not unreasonable in a world where drone technology has transformed warfare in Ukraine and elsewhere. But it also gives Beijing a powerful discretionary instrument. Every export license application becomes an opportunity to assess whether the buyer is aligned with Chinese interests. Countries that want to develop their own drone industries must navigate a paradox: to reduce dependence on China, they need research and development capacity that, in many cases, depends on Chinese components and knowledge. The global drone industry is still young, but it has already matured into a structure that makes independent production extraordinarily difficult outside China. Governments can mandate local assembly, but local assembly is not the same as local sovereignty. The real choke point, again, is less about the final product and more about the layers of technology inside it. Breaking that cycle will require not just money and political will, but a full-scale rebuilding of industrial ecosystems from the ground up.

Prescription for Dependence: The Quiet Pharmaceutical Crisis

Perhaps no sector demonstrates the human consequences of supply chain dependency more clearly than pharmaceuticals. During the COVID-19 pandemic, countries around the world suddenly discovered that many of the drugs their hospitals relied on — from antibiotics to paracetamol — were manufactured with active pharmaceutical ingredients, or APIs, coming overwhelmingly from China and India. India, in turn, depends on China for nearly three-quarters of its bulk drug intermediates. That means a very large share of the world’s generic medicine supply chain runs directly through Chinese chemical plants and manufacturing facilities. The pandemic exposed this vulnerability when Chinese factories shut down as cities locked down, disrupting supply chains for essential medicines in dozens of countries. Drug shortages, which had long been considered a specialized problem for developing nations, suddenly became a serious concern in rich countries as well. Governments began stockpiling essential medicines, but stockpiles are only a temporary solution. Rebuilding pharmaceutical manufacturing capacity requires enormous investment, years of regulatory approval, and a complex supply network that most Western countries allowed to dissolve in the pursuit of cheaper drug prices.

Now China is making that rebuilding even more difficult. Recent changes to Chinese export controls have touched pharmaceutical manufacturing technologies, including equipment and chemical processes used to produce critical inputs for generic drugs. Chinese authorities insist their measures are consistent with international standards, but the practical effect is that Western pharmaceutical companies face new barriers when trying to acquire the technology and materials needed to produce medicines outside China. The issue is especially acute for antibiotics and sterile injectables, both of which have been flagged by public health agencies in the United States and Europe as high-risk categories. Every time a new drug shortage is announced in an American hospital or a British pharmacy, the underlying cause can often be traced back to a fragile network of factories and suppliers that begins, still, in China. This is not a problem that can be solved by applauding domestic manufacturing initiatives or announcing innovation grants. The pharmaceutical industry is one of the most heavily regulated sectors in the global economy, and bringing a new production line online takes years. Meanwhile, China’s pharmaceutical engineers and chemical process experts are developing their own intellectual property, making it ever more likely that future medicines will be invented, developed and produced first in China. That is a shift that public health officials should regard with deep concern.

A Coherent Strategy of Enforced Interdependence

What connects these sectors, from solar and drones to medicines, is not just Chinese market share. It is a deliberate strategic posture that economists increasingly describe as “enforced interdependence.” The goal is not to cut off exports, but to make the continuation of those exports depend on Beijing’s goodwill. This gives the Chinese government influence not only over prices and availability but over the industrial decisions of foreign governments and corporations. Export controls are calibrated so that they do not immediately hurt global customers too much, but they create enough unpredictability to discourage strategic investment in alternatives. A company thinking about building a solar wafer factory outside China, or a drone motor assembly plant in Europe, or a pharmaceutical API facility in the United States, must calculate whether Chinese equipment suppliers will be allowed to provide the machinery needed for that facility. Even if the equipment is already installed, ongoing maintenance, spare parts, software updates and technical support can be controlled from Beijing. That is the deeper meaning of dependency: it is not only about buying products from China, but about relying on Chinese technology to keep your independent operations alive.

This approach fits within a broader vision of industrial policy that Chinese leaders have articulated for years, especially through concepts such as “dual circulation” and the Made in China 2025 initiative. The idea is to reduce China’s dependence on foreign technology while increasing foreign dependence on Chinese technology. It is a symmetrical strategy, but one that naturally advantages the country with the larger manufacturing base and the more integrated supply chains. Western attempts to counter it have so far been fragmented. Tariffs can raise prices on Chinese goods, but they cannot compel the development of a domestic supplier of a component that barely exists outside China. Subsidies can encourage companies to build factories, but they cannot instantly recreate the accumulated knowledge of entire industrial ecosystems. Diplomacy can forge alliances and promote “friendshoring,” but friends also have their own national interests and their own dependencies. What the West is only beginning to understand is that this is not a trade dispute. It is a structural transformation of global supply chains in which China is playing a long game with remarkable discipline and patience.

The Long Road to Autonomy: What Comes Next

The lesson of rare earths was supposed to be simple: diversify or be held hostage. Yet the subsequent years have shown that diversification is far more difficult when the dependency is embedded in advanced technology and manufacturing processes. Mines can be opened and minerals can be processed with enough time and money. But recreating entire ecosystems of solar manufacturing equipment, drone component production and pharmaceutical chemical capacity requires decades, not a single budget cycle. It requires training a workforce, building research and development networks, developing specialized suppliers, and establishing regulatory frameworks that encourage rather than hinder domestic production. No major country today is prepared to do that quickly. Even the most ambitious Western plans for supply chain resilience remain tethered to Chinese inputs at one level or another. Some companies are quietly accepting that “managed dependence” is more realistic than full independence. Others are investing in niche areas where they believe they can create alternatives, but those alternatives remain small relative to the enormous scale of Chinese output.

What is clear is that the world has entered a new era of economic statecraft. Rare earths were not an anomaly, and they were not the endgame. They were a warning shot, a signal that China understands the power its manufacturing ecosystem provides. Now that signal has been extended to solar technology, drones and drugmaking, the countries that consume and rely on these technologies can no longer pretend otherwise. The question is not whether China will lose its grip, because in the medium term it almost certainly will not. The question is whether the rest of the world can learn the deeper lesson before the next crisis arrives. The era of unquestioned globalized supply chains is over, and the new era is one of careful, strategic calculation. In that era, the countries that will be strongest are not those with the largest armies or the loudest rhetoric. They will be those that understand that true security begins with the humble machines, chemical processes and skilled engineers that keep a society running. And for now, China has invested more deeply and more wisely in those foundations than anyone else. That is not a story that can be fixed with a single headline or one new law. It is a challenge that will define the next decade of global politics, and one that no country can afford to ignore.